Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001437749-18-021874
Filing Date
2018-12-11
Accepted
2018-12-11 10:16:55
Documents
1
Period of Report
2018-12-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 rdgdoc.html 3  
1 FORM 3 rdgdoc.xml 3 1343
  Complete submission text file 0001437749-18-021874.txt   2847
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Issuer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 9301 AMBERGLEN BOULEVARD, SUITE 100 C/O MOLECULAR TEMPLATES, INC. AUSTIN TX 78729
Business Address
Cutler Adam D. (Reporting) CIK: 0001722673 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35076 | Film No.: 181227958